Jianfan Biotech (300529.SZ) announced semi-annual results, with net profit of 382 million yuan to mother, a year-on-year decrease of 1.99%

According to Zhitong Finance App News, Jianfan Biotech (300529.SZ) released its 2026 semi-annual report. In the first half of 2026, the company achieved operating income of 1,032 million yuan, a year-on-year decrease of 8.99%; realized net profit attributable to shareholders of listed companies of 382 million yuan, a year-on-year decrease of 1.99%; realized net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses of 355 million yuan, a year-on-year decrease of 4.71%; basic earnings per share were 0.49 yuan.

During the reporting period, due to external factors such as fluctuations in industry demand and increased market competition, the company's overall revenue declined year on year; during the reporting period, the company optimized its organizational structure, strengthened cost control, and overall cost reduction and efficiency, which combined led to a year-on-year decline in net profit less than the proportion of revenue decline. During the reporting period, the company's net operating cash flow was 411 million yuan, exceeding the current net profit attributable to mother by 29 million yuan. The company's cash flow and profit quality remained at a high level. The company's gross profit margin of 78.46% and net profit margin of 37% remain at a high level, and the company's overall profitability remains strong.